REG - Proteome Sciences - Contract Win

Proteome SciencesAnnouncement

21/02/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250221:nRSU9398Xa&default-theme=true

RNS Number : 9398X  Proteome Sciences PLC  21 February 2025

 

 

Prior to publication, the information contained within this announcement was
deemed by the Company to constitute inside information as stipulated under the
UK Market Abuse Regulations. With the publication of this announcement, this
information is now considered to be in the public domain.

21 February 2025

Proteome Sciences plc

("Proteome Sciences" or the "Company")

 

Substantial contract for Proteome Sciences

Proteome Sciences (AIM:PRM), is pleased to announce that the Company has
secured a contract win from a US biopharmaceutical company using the Company's
mass spectrometry services for the analysis of samples for an on-going
clinical trial. This project will be provided utilising the Good Clinical
Laboratory Practice ("GCLP") accreditation obtained by Proteome Sciences
specifically for this type of project. The contract value is in excess of
US$1m and the Company considers that a significant proportion of the work
should be completed in the current financial year and into 2026.

Commenting on the contract, Richard Dennis, Chief Commercial Officer of
Proteome Sciences said:

"In April 2024 we announced the first contract from this customer and
commented that we expected additional contracts to be received from them in
the near future. This contract represents a further targeted assay that we
will perform under GCLP compliance to monitor drug performance in an ongoing
clinical trial.   As in 2024 we are seeing increasing interest for GCLP work
from other major biopharma clients in both the US and Europe and expect
additional orders to follow in 2025."

- Ends -

For further information:

 Proteome Sciences plc
 Dr. Ian Pike, Chief Scientific Officer                                Tel: +44 (0)20 7043 2116
 Richard Dennis, Chief Commercial Officer

 Allenby Capital Limited (Nominated Adviser & Broker)
 John Depasquale/Lauren Wright (Corporate Finance)                     Tel: +44 (0) 20 3328 5656

 Tony Quirke/Stefano Aquilino (Equity Sales & Corporate Broking)

About Proteome Sciences plc. (www.proteomics.com (http://www.proteomics.com/)
)

 

Proteome Sciences plc is a specialist provider of contract proteomics services
to enable drug discovery, development and biomarker identification, and
employs proprietary workflows for the optimum analysis of tissues, cells and
body fluids. SysQuant® and TMT®MS2 are unbiased methods for identifying and
contextualising new targets and defining mechanisms of biological activity,
while analysis using Super-Depletion and TMTcalibrator™ provides access to
over 8,500 circulating plasma proteins for the discovery of disease-related
biomarkers. Targeted assay development using mass spectrometry delivers high
sensitivity, interference-free biomarker analyses in situations where standard
ELISA assays are not available.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  CNTEAPAEAAFSEFA